Sulzer Medica In Talks To Divest Electrophysiology Division By August
This article was originally published in The Gray Sheet
Sulzer Medica's next-generation Res-Q Micron implantable cardioverter defibrillator system, clinical trials for which will begin later this year, could be a major draw for potential acquirers of the firm's electrophysiology division.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.